A Phase 1 interventional study of NNC0442-0344 A and Placebo in Haemophilia A, sponsored by Novo Nordisk A/S. Completed at 2 sites in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 13th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2024, is one of 27 in phase 1, and was the 86th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States, Austria, Belgium and 9 more countries
Ages 18–64 · Men only · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 12+
Novo Nordisk A/S · Sites in India, Malaysia, Korea, Republic of and 1 more country
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2024.
This study's enrollment of 95 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 38 across the 59 interventional studies, 86 across the 32 observational. Of the 78 that completed or were terminated, 20 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
4 of the studies in Hemophilia A by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04682145Novo Nordisk A/SAdverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol | 2026-12-01 |
| NCT07653139Novo Nordisk A/SPatient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany | 2026-12-26 |
| NCT07220564Novo Nordisk A/SA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | 2027-02-05 |
| NCT04574076Novo Nordisk A/SA Study Following Males With Haemophilia A on Prophylaxis With Esperoct® | 2027-06-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test how different doses of study medicine (Inno8) work in the healthy men. The purpose of this study is to prove safety of Inno8 in healthy men, which will support further development of Inno8 in people with Haemophilia A. The study consists of three parts: single ascending dose (SAD), multiple ascending dose (MAD) and single subcutaneous dose (SSD). Each part will have more than one cohort (like sub-parts). No matter which part the participants will be enrolled in, they will either get the study medicine (Inno8) or a dummy medicine that looks like the study medicine but has no effect on the body (placebo). Which treatment participants get is decided by chance. The study medicine is a new medicine that cannot be prescribed by doctors. In the SAD and SSD part participants will receive a single injection of study medicine or placebo, and the study will last for up to 9 weeks. In the MAD part, participants will receive 1-2 tablets of study medicine or placebo daily for 10 days, and the study will last for up to 11 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of NNC0442-0344 A intravenously.
Drug: NNC0442-0344 A
Participants will receive single dose of NNC0442-0344 A intravenously.
Drug: NNC0442-0344 A
Participants will receive single dose of NNC0442-0344 A intravenously.
Drug: NNC0442-0344 A
Participants will receive single dose of NNC0442-0344 A intravenously.
Drug: NNC0442-0344 A
Participants will receive single dose of NNC0442-0344 A intravenously.
Drug: NNC0442-0344 A
Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
Drug: NNC0442-0344 A
Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
Drug: NNC0442-0344 A
Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
Drug: NNC0442-0344 A
Participants will receive a oral daily dose of NNC0442-0344 A for 10 days.
Drug: NNC0442-0344 A
Participants will receive single dose of NNC0442-0344 A subcutaneously.
Drug: NNC0442-0344 A
Participants will receive single dose of NNC0442-0344 A subcutaneously.
Drug: NNC0442-0344 A
Participants will receive single dose of placebo intravenously.
Drug: Placebo
Participants will receive a oral daily dose of Placebo for 10 days.
Drug: Placebo
Participants will receive single dose of placebo subcutaneously.
Drug: Placebo
SAD: NNC0442-0344 A will be administered intravenously. MAD: NNC0442-0344 A will be administered orally. SSD: NNC0442-0344 A will be administered subcutaneously.
Also known as: Inno8
SAD: Placebo will be administered intravenously. MAD: Placebo will be administered orally. SSD: Placebo will be administered subcutaneously.
SAD: Number of treatment emergent adverse events
Measured as count of events.
Time frame: From time of dosing (Day 1) to Day 36
MAD: Number of treatment emergent adverse events
Measured as count of events.
Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)
SSD: Number of treatment emergent adverse events
Measured as count of events.
Time frame: From time of dosing (Day 1) to Day 36
SAD: Change in D-dimer
Measured as absolute and percentage (%).
Time frame: From baseline (Day 1) to Day 36
SAD: Change in prothrombin fragment 1 and 2
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SAD: Change in fibrinogen
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SAD: Change in platelets
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SAD: Cmax, SD: the maximal concentration of Inno8 after a single dose
Measured as nanograms per millilitre (ng/mL).
Time frame: From baseline (Day 1) to Day 36
SAD: AUC, SD: the area under the concentration curve of Inno8 after a single dose
Measured as nanograms\*day per millilitre (ng\*day/mL).
Time frame: From baseline (Day 1) to Day 36
SAD: T1/2, SD: the terminal half-life of Inno8 after a single dose
Measured as days.
Time frame: From baseline (Day 1) to Day 36
SAD: Maximum change in activated partial thromboplastin time
Measured as seconds.
Time frame: From baseline (Day 1) to Day 36
SAD: Maximum thrombin generation (peak height)
Measured as nanomolar (nM).
Time frame: From baseline (Day 1) to Day 36
MAD: Change in D-dimer
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 46
MAD: Change in prothrombin fragment 1 and 2
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 46
MAD: Change in fibrinogen
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 46
MAD: Change in platelets
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 46
MAD: Occurrence of anti-Inno8 antibodies
Measured as count.
Time frame: From baseline (Day 1) to Day 46
MAD: Cmax: The maximum concentration of Inno8 after multiple doses
Measured as ng/mL.
Time frame: From Day 10 to Day 11
MAD: Tmax: The time to Cmax after last multiple dose
Measured as hours.
Time frame: From Day 10 to Day 11
MAD: Tmax: The time to Cmax after first dose
Measured as hours.
Time frame: From Day 1 to Day 2
MAD: AUC: the area under the Inno8 concentration-time curve in the dosing interval after multiple doses
Measured as ng\*day/mL.
Time frame: From Day 10 to Day 11
MAD: Maximum thrombin generation (peak height)
Measured as nM.
Time frame: From Day 10 to Day 11
SSD: Change in D-dimer
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SSD: Change in prothrombin fragment 1 and 2
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SSD: Change in fibrinogen
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SSD: Change in platelets
Measured as absolute and %.
Time frame: From baseline (Day 1) to Day 36
SSD: Cmax, SD: the maximal concentration of Inno8 after a single dose
Measured as ng/mL.
Time frame: From baseline (Day 1) to Day 36
SSD: AUC, SD: the area under the concentration curve of Inno8 after a single dose
Measured as ng\*day/mL.
Time frame: From baseline (Day 1) to Day 36
SSD: T1/2, SD: the terminal half-life of Inno8 after a single dose
Measured as days.
Time frame: From baseline (Day 1) to Day 36
SSD: Maximum change in activated partial thromboplastin time
Measured as seconds.
Time frame: From baseline (Day 1) to Day 36
SSD: Maximum thrombin generation (peak height)
Measured as nanomolar (nM).
Time frame: From baseline (Day 1) to Day 36
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Mar 2026, 18 months.
Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NNC0442-0344